**4. Conclusions**

In summary, we have designed a new class of dendritic amphiphiles self-assembling into vesicle-like nanosized supramolecular associates (dendrimersomes). Rationally designed molecular topology of dendrons permits to use simple procedures to yield monodisperse nanoparticles. Because the reorganization is driven by subtle changes of ambient pH, triazine-carbosilane dendrimersomes can be useful as carriers for the delivery of sensitive, poorly soluble or highly toxic compounds into cells. As a proof-of-concept study, we attempted to encapsulate anti-cancer drugs doxorubicin and methotrexate and to deliver them into human leukaemia cells. The encapsulation, though efficient, does not change the vesicular topology of nanoconstructions. Drug-loaded dendrimersomes efficiently penetrate into cells and induce cell death. Our findings suggest that triazine-carbosilane dendrimersomes hold considerable potential for nanomedicine as stimuli-sensitive drug carriers.

**Supplementary Materials:** The following are available online at http://www.mdpi.com/2079-4991/10/10/1899/ s1, Figure S1: Kinetic profiles of the doxorubicin release; Figure S2: Dendron biocompatibility; Figure S3: Flow cytometry plots; Figure S4: Fluorescence microscopy images; Figure S5: Flow cytometry plots.

**Funding:** This study was supported by RFBR grant No. 18-33-20109, grant of the President of the Russian Federation No. MK-2278.2019.4, by MINECO grant CTQ-2017-85224-P, Consortium NANODENDMED-II-CM

**Author Contributions:** Conceptualization, N.K., E.P., E.A.; methodology, N.K., E.P., J.P., J.S.-N., E.A.; investigation, N.K., V.A., E.P., A.A., J.P., E.A.; data curation, N.K., V.A., J.P., E.P., E.A.; writing—original draft preparation, N.K., E.P., E.A.; writing—review and editing, F.J.d.l.M., R.G., E.A.; visualization, N.K., J.P., E.A.; supervision, F.J.d.l.M., R.G., E.A.; funding acquisition, F.J.d.l.M., R.G., E.A. All authors have read and agreed to the published version of the manuscript.

(B2017/BMD-3703) and IMMUNOTHERCAN-CM (B2017/BMD3733). The project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 844217. This article is based upon work from COST Action CA 17140 "Cancer Nanomedicine from the Bench to the Bedside" supported by COST (European Cooperation in Science and Technology). CIBER-BBN is an initiative funded by the VI National R&D&i Plan 2008–2011, Iniciativa Ingenio 2010, Consolider Program, CIBER Actions and financed by the Instituto de Salud Carlos III with assistance from the European Regional Development Fund. E.A. appreciates the financial support through the Gíner de los Ríos scholarship from the University of Alcalá.

**Acknowledgments:** The authors thank Margarita Barkovskaya (RIFCI) for fluorescence microscopy images as well as Alya Venyaminova (ICBFM) and Vladimir Kozlov (RIFCI) for the management support.

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
